|
IMMUNODEFICIENCY 22
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Primary T-cell immunodeficiency with immunodysregulation caused by autosomal recessive LCK deficiency.
|
22985903 |
2012 |
|
IMMUNODEFICIENCY 22
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Defect of lck in a patient with common variable immunodeficiency.
|
11351273 |
2001 |
|
IMMUNODEFICIENCY 22
|
0.700 |
GermlineCausalMutation
|
disease |
ORPHANET |
|
|
|
|
IMMUNODEFICIENCY 22
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
IMMUNODEFICIENCY 22
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Combined immunodeficiency
|
0.310 |
Biomarker
|
disease |
BEFREE |
On the basis of its function, we considered LCK a candidate gene in patients with combined immunodeficiency.
|
22985903 |
2012 |
|
Combined immunodeficiency
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Defect of lck in a patient with common variable immunodeficiency.
|
11351273 |
2001 |
|
HIV Infections
|
0.210 |
Biomarker
|
group |
RGD |
HIV-1 transgenic rat CD4+ T cells develop decreased CD28 responsiveness and suboptimal Lck tyrosine dephosphorylation following activation.
|
16828835 |
2006 |
|
HIV Infections
|
0.210 |
Biomarker
|
group |
BEFREE |
Several studies have suggested an important role for the protein tyrosine kinase p56lck (Lck) in HIV infection; however, the exact nature of this role remains unclear.
|
12823281 |
2003 |
|
Allergic Conjunctivitis
|
0.200 |
Biomarker
|
disease |
RGD |
Ag-specific recognition, activation, and effector function of T cells in the conjunctiva with experimental immune-mediated blepharoconjunctivitis.
|
14507881 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, PTPN2 deletion in T cells expressing a chimeric antigen receptor (CAR) specific for the oncoprotein HER-2 increased the activation of the Src family kinase LCK and cytokine-induced STAT-5 signalling, thereby enhancing both CAR T-cell activation and homing to CXCL9/10-expressing tumours to eradicate HER-2<sup>+</sup> mammary tumours in vivo.
|
31803974 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, Lck has emerged as a novel druggable target molecule for the treatment of cancer and neuronal diseases.
|
31315298 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
LCK expression was compared to CYT across tumor types available in the TCGA and was a significant predictor of prognosis in HGSOC where CYT was not predictive.
|
31515669 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although humoral responses against CTL epitope peptides from lymphocyte-specific protein tyrosine kinase (Lck) antigen have been observed in the majority of healthy donors and cancer patients, the biological activity of the antibody has not been determined.
|
29388341 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
All TAA coding candidate peptides used in PPV treatment were expressed in tumor cells from prostate cancer and UC samples except for p56Lck in both, and prostate-specific antigen (PSA), prostatic acid phosphatase (PAP) and prostate-specific membrane antigen (PSMA) in the UC samples.
|
29938870 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tyrosine kinases including LCK and FMS are involved in inflammatory disorders as well as many types of cancer.
|
29107425 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, cells expressing LCK developed tumor earlier compared to cells transfected with empty control vector.
|
29062038 |
2017 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We demonstrate a novel mutation in LCK in a family affected by atypical EV with T-cell defects, HPV infection and virus-induced malignancy, providing new clues in the understanding of host defences against HPV and better genetic counselling of patients with the EV phenotype.
|
27087313 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High expression of T-cell and B-cell signatures predicted improved overall survival across many tumor types including breast, lung, and melanoma (breast CD8_T_Cells hazard ratio [HR] = 0.36, 95% confidence interval [CI] = 0.16 to 0.81, P = .01; lung adenocarcinoma B_Cell_60gene HR = 0.71, 95% CI = 0.58 to 0.87, P = 7.80E-04; melanoma LCK HR = 0.86, 95% CI = 0.79 to 0.94, P = 6.75E-04).
|
27335052 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All together, our results support a novel function of nuclear Lck in promoting human leukemic T cell survival through interaction with a tumor suppressor.
|
25997448 |
2015 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this study, we identified lymphocyte-specific protein tyrosine kinase (LCK), which correlates with cancer malignancy, as a binding partner of FOXP3.
|
24155921 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Stimulation of apoptosis required interaction between the tumor and T-cells, presence of p56lck and ZAP70, decrease of mitochondrial membrane potential and caspase activation.
|
19874850 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was no statistical association between PTKs and IL-10 in the tumor but more than 50% of cases who express IL-10 lost p56(lck), p59(fyn).
|
18651178 |
2009 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, CD8alpha down-regulates the production of major Th2-type cytokines, in part mediated by LCK and/or linker for activation of T cells, and may induce differentiation of tumor-specific Th1 cells, which makes this coreceptor an interesting candidate to improve the clinical potential of TCR gene transfer to treat cancer.
|
16818755 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Most lymphomas of germinal center origin (e.g. follicular lymphoma) and also many mantle cell lymphomas, chronic lymphocytic leukemia (CLL) and most T-cell neoplasms expressed LCK.
|
16769579 |
2006 |